Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 28, 2021 1:02pm
82 Views
Post# 33286832

RE:RE:Insiders

RE:RE:InsidersI would like to know who is intraday shorting the stock. The short volume was averaging about 20% for quite a while but in the last few days we had sessions with over 40% of total trading volume and the volume has been historically low. The  short interest for THTX on monthly basis almost were some 40% lower so these are traders/penny chasers  who short the stock and cover it in the same session or following sessions.
Again the company needs to create narratives for investors and not traders to buy the stock for a medium to long term returns. So whatever plan they are working on they need to put it on action ASAP. Recall one of the reasons for the offering was a market correction well if they believe that's the case then get the plan going before the presumed bear market.

Market Date Short Volume Total Volume
(MM Shares)
Short Volume Ratio
2021-05-27 4,761 0.03 17.00
2021-05-26 8,548 0.02 41.90
2021-05-25 24,843 0.05 52.41
2021-05-24 4,825 0.04 11.33
2021-05-21 20,824 0.07 31.50
2021-05-20 14,652 0.05 26.93
2021-05-19 24,897 0.08 32.13
2021-05-18 39,383 0.11 35.45
2021-05-17 42,493 0.12 35.35
2021-05-14 20,909 0.10 20.36
 



<< Previous
Bullboard Posts
Next >>